SARS-CoV-2 and Multisystem Inflammatory Syndrome In Children (MIS-C)

Curr Probl Pediatr Adolesc Health Care. 2021 Apr;51(4):101000. doi: 10.1016/j.cppeds.2021.101000. Epub 2021 May 12.

Abstract

The novel SARS-CoV-2 virus has affected children and adolescents throughout the world since its discovery in 2019. For many children, infection with SARS-CoV-2 presents as an asymptomatic to mild infection. However, in a small subset of children who become infected with the SARS-CoV-2 virus, a more severe post-infectious inflammatory illness has emerged, referred to as Multisystem Inflammatory Syndrome in Children (MIS-C). Since its discovery in 2020, the scientific community has learned a lot about the presentation, evaluation, treatment, and management of MIS-C.

Publication types

  • Review

MeSH terms

  • Adolescent
  • COVID-19 / diagnosis
  • COVID-19 / epidemiology*
  • COVID-19 / therapy
  • Child
  • Humans
  • SARS-CoV-2
  • Severity of Illness Index
  • Systemic Inflammatory Response Syndrome / diagnosis
  • Systemic Inflammatory Response Syndrome / epidemiology*
  • Systemic Inflammatory Response Syndrome / therapy

Supplementary concepts

  • pediatric multisystem inflammatory disease, COVID-19 related